Tepotinib
The medication you're asking about is tepotinib, a MET tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations, and peripheral edema (leg swelling) is one of its most common and characteristic adverse effects. 1
Why Tepotinib Causes Leg Swelling
Tepotinib is FDA-approved for metastatic NSCLC with MET exon 14 skipping mutations 1. The mechanism of peripheral edema involves treatment-related increases in vascular permeability, though the exact pathophysiology remains incompletely understood 2.
Clinical Evidence on Edema Risk
The VISION phase II trial demonstrated that:
- Grade 3 or higher adverse events occurred in 28% of patients, with peripheral edema being prominent
- 11% of patients had to permanently discontinue tepotinib specifically due to peripheral edema, pleural effusion, or dyspnea 1
A comprehensive meta-analysis of MET inhibitors showed that tepotinib carries a significantly elevated risk of peripheral edema compared to controls, with both all-grade and high-grade edema being substantially increased 3.
Efficacy Data
Despite the edema risk, tepotinib demonstrates meaningful clinical benefit:
- Treatment-naïve patients: 57.3% objective response rate with median duration of response of 46.6 months
- Previously treated patients: 45% objective response rate with median duration of response of 12.6 months
- Combined analysis: PFS of 8.5 months 1
Management Considerations
When Edema Becomes Intolerable
If peripheral edema becomes intolerable on tepotinib, switching to capmatinib (another MET inhibitor) may allow continuation of MET-targeted therapy, as these agents have different edema profiles despite similar mechanisms of action 4. This is clinically important because it allows patients to continue benefiting from MET inhibition without the limiting toxicity.
Alternative MET Inhibitors for NSCLC
The NCCN Guidelines recommend three MET inhibitors for MET exon 14 skipping mutations 1:
- Capmatinib (preferred)
- Tepotinib (preferred)
- Crizotinib (useful in certain circumstances)
Capmatinib and tepotinib are both categorized as preferred options, but capmatinib may have a more favorable edema profile based on case reports of successful switching 4.
Clinical Pitfall
Do not confuse MET inhibitor-induced edema with cellulitis or other infectious processes. The bilateral, symmetric nature and association with MET inhibitor therapy should prompt consideration of drug-related etiology rather than reflexive antibiotic treatment 2.